tbuckley/cabot-search huggingface dataset:
National Bullying Prevention Awareness Month — October 1–31, 2015
Authors: Kristen Gray, Eduardo Valverde, Tian Tang, Azfar-E-Alam Siddiqi, ; Hall, Thomas Frieden, Harold Jaffe, Joanne Cono, Chesley Richards, Michael Iademarco, Sonja Rasmussen, Charlotte Kent, Jacqueline Gindler, Teresa Rutledge, Douglas Weatherwax, Soumya Dunworth, Teresa Hood, Jude Rutledge, Martha Boyd, Maureen Leahy, Julia Martinroe, Stephen Spriggs, Brian Wood, Moua Yang, Quang Doan, Phyllis King, Teresa Moreland, Terraye Starr, Timothy Jones, Matthew Boulton, Virginia Caine, Katherine Daniel, Jonathan Fielding, David Fleming, William Halperin, King Holmes, Robin Ikeda, Rima Khabbaz, Phyllis Meadows, Jewel Mullen, Jeff Niederdeppe, Patricia Quinlisk, Patrick Remington, Carlos Roig, William Roper, William Schaffner, Regina Simeone, Brigette Gleason, John Redd, Peter Kilmarx, Tom Sesay, Francis Bayor, Antons Mozalevskis, Allison Connolly, James Akpablie, Dimitri Prybylski, Daphne Moffett, Michael King, Micah Bass, Kristy Joseph, Jefferson Jones, Francis Ocen, Amelia Kasper, Amanda Kamali
Journal: MMWR Morbidity and Mortality Weekly Report (2015)

National Latino AIDS Awareness Day is observed each year on October 15 to focus on the continuing and disproportionate impact of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) on the Hispanic or Latino population in the United States.Hispanics or Latinos represent approximately 17% of the U.S. population (1); however, in 2013, they accounted for 21% of all new diagnoses, corresponding to a rate of 18.7 per 100,000 (2).In 2011, an estimated 242,000 Hispanics or Latinos were living with HIV infection in the United States, representing 20% of all such persons.Of these Hispanics or Latinos, an estimated 85% had received a diagnosis of HIV infection, 40% were engaged in HIV medical care, 37% had received a prescription for antiretroviral therapy, and 31% had achieved viral suppression (3).National Latino AIDS Awareness Day is an opportunity to encourage increased HIV prevention activities, such as HIV testing, for Hispanics or Latinos.CDC supports testing, linkage to and engagement in care and treatment, and a range of other efforts to reduce the risk for acquiring or transmitting HIV infection among Hispanics or Latinos.Additional information about CDC resources and activities for National Latino AIDS Awareness Day is available at http://www.cdc.gov/Features/LatinoAIDSAwareness.Additional information about HIV among Hispanics or Latinos is available at http:// www.cdc.gov/hiv/risk/racialethnic/hispanicslatinos.Hispanics or Latinos* represent about 17% of the total U.S. population and are disproportionately affected by human immunodeficiency virus (HIV) infection in the United States (1,2).In 2013, the rate of HIV diagnosis among Hispanics or Latinos (18.7) was nearly three times that of non-Hispanic * Hispanics or Latinos can be of any race.
Smoking, alcohol, and neuromuscular function in older women
Authors: J. Slade
Journal: JAMA (1995)

<h3>In Reply.</h3> —We used empirical data on treatments and outcomes of elderly AMI patients to estimate the mortality consequences of the additional catheterization and revascularization procedures performed by the most intensive hospitals relative to other hospitals. In contrast, Drs Kuller and Detre postulate that invasive procedures prevent death in 1 year in a substantial portion (one fourth) of the 26.2% of patients who received them. Further, their claim that randomized trials can answer this question is inaccurate. Under ideal circumstances, a standard randomized controlled trial estimates the average effect of treatment over an entire study population. Because we suspect that invasive procedures are highly effective in certain kinds of elderly AMI patients and ineffective in others, we instead sought to estimate the average effect on mortality for "incremental" changes in use of these procedures within the population of elderly AMI patients. A more complete discussion of the differences between population
Angiographic Findings in a Case of Brain Syphilis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Endometrial cancer in relation to patterns of menopausal estrogen use
Authors: N. S. Weiss
Journal: JAMA (1979)

Female residents of King County, Washington, in whom endometrial cancer developed between January 1975 and April 1976 were interviewed concerning prior use of menopausal estrogens. Their responses were compared with those of a random sample of women from the same population. Among current estrogen users, endometrial cancer risk was strongly related to duration of use; although only a minimal elevation of risk was present during the first two years, there was a rapid rise to a 20-fold excess after about ten to 15 years. Cessation of estrogen use led to a decline in incidence of endometrial cancer within several years, but the risk remained higher than in nonusers through the first decade after administration of the drug was stopped. Risk was elevated whether or not the regimen was cyclic and whether conjugated or other types of estrogens had been used. Dosages of less than 0.625 mg/day of conjugated estrogens produced a smaller increase in risk than did other dosages. (<i>JAMA</i>242:261-264, 1979)
Medical uses of radiation
Authors: J. F. Walker
Journal: JAMA (1971)

<h3>To the Editor.—</h3> I was surprised and disappointed to find Sagan's communication (<b>215</b>:1977, 1971) given the status of an<i>editorial</i>. It is a superficial and incomplete comment which overlooks the very real efforts made by the American Medical As sociation and many other medical organizations to educate physicians about radiation. If allowed to stand unchallanged, it would serve as prima facie argumentation for the government intervention which Sagan professes to deplore. This is not to dissent from Sagan's conclusions that physicians need to be more aware of good and bad uses of radiation. This has been a theme of efforts by the AMA, the American College of Radiology, and other groups for more than 40 years. The potential hazard of radiation, the shortage of radiologists and their facilities, and even the impact of extensive x-ray film examinations on the patient's pocketbook are all valid reasons for encouraging physicians to
Women in Medicine
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE OUTLOOK IN NUTRITION
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction
Journal: BMJ (1924)

TREATTMENT oF ASTHMA.("J.G. G." asks for stugoestions for the treatment of a lady at-el 60, who has suffered from asthma for five years.Her present attack has tasted over sixmonths.There is no history * f heredity or neuroiis, and there is no naso-pharyngeal abuiorintlity.Potassium iodide over prolonged perio-ds, adrenaline, in.)rphine, lobelia, stramonium, and the exclusion of cats, leathers, etc., have all proved failures.LIQUID PARAFFIN AND CANCER.Di'. S. WATSON SMITH (Bournemouth) writes: In your issu-e of November Ist, p. 840, ' i. K." asks whether those who see nmany c:tses of m-lalignaut (disease of the alimentary tract suspect the taking of liqui(d paraffin as a cause.Shortly after liquid paraffln c etne into more general use, thte late Dr. Allan Jamieson of E, litiburgh, in a letter to the BRITISH MEDICAL JOURNAL, issued aL \V.rtnngi1r adll a reminider of the fact that paraffin workers were, 0:1 alccounit of their employment, particulatly liable to cancer.At enlormous amount of paraffin, solid as well as liquid, must be c ;nsumed dadly in this country, and chiefly by those who are vist the ag,e of full deveiopment.One cannot easily avoid u,rdering it when so many preparations and so-called "foods" lhave par&alTn entering into their composition.Even with a guarantee it is impossible to be absolutely certain of purity or of the absence of all impurity.Paraffin used in ointments and pastes seems to harm few skins; if it cannot be tolerated, antother vehicle is substituted.It has, however, to be remem- listed that ointmenits containring paraffins have only an occa- sional use for any particular patient and for seldom longer than inaNs or weeks at a time.Taken internally for montths or years, a'Ls it comnmonly is nowadays, may make all the difference in r:sk, and the few who have the misfortutne not to tolerate paraffin weil may run a greater risk of fututre malignant trouble.AWithin the past few years I have seen three cases of a dry form ot dermatitis of both hands in motor-ear mechanics, apparently caused by h&ndling petrol and lubricants.It is understood that
Leads from the MMWR. Outbreak of hemorrhagic colitis--Ottawa, Canada
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Flow Diagram Randomization Boxes
Journal: JAMA (2016)

Najib M. Rahman, DPhil; Justin Pepperell, MD; Sunita Rehal, MSc; Tarek Saba, MD; Augustine Tang, FRCS(C-Th); Nabeel Ali, MD; Alex West, MRCP; Gihan Hettiarachchi, MRCP; Dipak Mukherjee, FRCP; Johnson Samuel, FRCP; Andrew Bentley, MD; Lee Dowson, MRCP; Jonathan Miles, MRCP; C. Frank Ryan, FRCPC; Ken Y. Yoneda, MD; Anoop Chauhan, MD; John P. Corcoran, MRCP; Ioannis Psallidas, PhD; John M. Wrightson, DPhil; Rob Hallifax, MRCP; Helen E. Davies, MD; Y. C. Gary Lee, PhD; Melissa Dobson, BSc; Emma L. Hedley, RGN; Douglas Seaton, MD; Nicky Russell, RGN; Margaret Chapman, RGN; Bethan M. McFadyen, RN; Rachel A. Shaw, BA; Robert J. O. Davies, MD; Nick A. Maskell, DM; Andrew J. Nunn, MSc; Robert F. Miller, FRCP
REFORM IN RADIO ADVERTISING
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hemophilia Prophylaxis
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Marriages.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The <i>BRAF</i> and <i>NRAS</i> mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive mitogen‐activated protein kinase pathway activation
Authors: J.M. Tan, L.N. Tom, K. Jagirdar, D. Lambie, H. Schaider, R.A. Sturm, H.P. Soyer, M.S. Stark
Journal: British Journal of Dermatology (2018)

Most people have a few brown spots on their skin known as melanocytic naevi or moles. Moles are harmless but can occasionally transform into a potentially lethal tumour called malignant melanoma. Dermatologists recognise different types of mole from their appearance under a magnifying lens (dermatoscope). Broadly speaking: “globular” naevi appear early in life and may transform into melanoma; “reticular” naevi develop in adults and may be associated with melanoma arising at a site where no mole was present; reticular naevi with “peripheral globules” (PG) are growing but not malignant. Mutations (mistakes) in BRAF and NRAS genes occur in both benign and cancerous moles (malignant melanoma). These genes are components of the MAPK pathway which is important in tumour development. To try to clarify the role of these genes, these researchers in Australia looked for a relationship between dermoscopic appearance and NRAS and BRAF mutations in benign moles. They examined, dermoscopically, 40 acquired (non‐congenital) moles in 27 people then removed them for analysis. Under the microscope, disordered cell structure was observed in most reticular naevi but rarely in globular and PG naevi. Using a new, highly sensitive technique (“droplet digital PCR”) able to detect mutations in single cells, they found that most globular and all PG naevi had a BRAF mutation whereas reticular naevi had either BRAF or NRAS mutations. They conclude that all moles harbour mutations in MAPK genes, confirming a fundamental role for the MAPK pathway in the development of melanocytic naevi as well as melanoma.
NTOX-09. NEUROLOGICAL ADVERSE EVENTS ASSOCIATED WITH THE IMMUNE CHECKPOINT INHIBITORS: REVIEW OF THE LITERATURE AND CHARACTERIZATION OF THE CLINICAL PATTERNS
Authors: Stefania Cuzzubbo, Mathilde Tissier
Journal: Neuro-Oncology (2016)

Immune checkpoint inhibitors constitute a promising class of cancer treatment, but they are associated with several immune-related adverse events (irAEs). Common grade 3/4 irAEs include dermatitis, enterocolitis, hepatitis and hypophysitis. Much less characterized are the neurological complications (nAEs). To better define the neurological patterns of these nAEs, we reviewed the literature reporting neurological disorders associated with immune checkpoint inhibitors. A systematic search of literature up to February 2016 was conducted in PubMed database. Eligible studies included the case reports and the prospective trials (phase II and III). Patients with brain metastases or tumoral meningitis were excluded. A total of 67 patients having nAEs were described. In the clinical trials (58 trials, involving 9227 patients), the overall incidence of all-grade nAEs was 3.4% and 3.1% for the patients treated respectively with anti-CTLA4 and anti-PD-1. Overall incidence of high-grade nAEs was 0.5% for the anti-CTLA-4 group and 0.2% for the anti-PD-1 group. Lymphocytic meningitis and myasthenic syndromes were the most frequently nAEs reported. In the case reports, the most common nAEs related to CTLA-4 blockade included Guillain Barré syndromes and other radiculoneuropathies, meningoradiculitis, myasthenia gravis and less frequently lymphocytic meningitis, meningoencephalitis and myelitis. Anti-PD-1 treatments were mostly associated with central nervous system toxicity: encephalitis, cerebral vasculitis. Occurrence of nAEs was associated with tumor response in 29/32 patients. The median time of onset of nAEs was 6 and 7 weeks with anti-CTLA-4 and anti-PD-1 treatments, respectively. In almost all cases the outcome was favorable after drug interruption and steroids treatment. Neurological complications reported with immune checkpoint inhibitors are non-specific and pleomorphic, the most common being meningitis, radiculoneuropathy and myasthenic syndromes. In almost all cases, the outcome was favorable after drug interruption and steroid treatment. As suggested for other irAEs, nAEs may be associated with a clinical benefit and could be indicative for tumor-specific immune activation.
Social Medicine and Medical Economics
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal